Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

ClinicalTrials.gov ID: NCT05629962

Public ClinicalTrials.gov record NCT05629962. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 3:59 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.

Study identification

NCT ID
NCT05629962
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Enrollment
2,285 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 25, 2022 (Actual)
Primary completion
Apr 25, 2024 (Actual)
Completion
May 30, 2024 (Actual)
Last update posted
Jun 13, 2025

2022 – 2024

United States locations

U.S. sites
61
U.S. states
12
U.S. cities
49
Facility City State ZIP Site status
Atea Study Site Kingman Arizona 86401 —
Atea Study Site Prescott Arizona 86301 —
Atea Study Site Surprise Arizona 85378 —
Atea Study Site Tucson Arizona 85741 —
Atea Study Site Canoga Park California 91303 —
Atea Study Site Fullerton California 92835 —
Atea Study Site Inglewood California 90301 —
Atea Study Site La Palma California 90623 —
Atea Study Site Long Beach California 90805 —
Atea Study Site Long Beach California 98015 —
Atea Study Site Los Angeles California 90017 —
Atea Study Site Sacramento California 95817 —
Atea Study Site San Diego California 92120 —
Atea Study Site Coral Gables Florida 33134 —
Atea Study Site Cutler Bay Florida 33189 —
Atea Study Site Doral Florida 33172 —
Atea Study Site Hialeah Florida 33010 —
Atea Study Site Miami Florida 33125 —
Atea Study Site Miami Florida 33135 —
Atea Study Site Miami Florida 33155 —
Atea Study Site Miami Florida 33165 —
Atea Study Site Miami Florida 33173 —
Atea Study Site Miami Florida 33184 —
Atea Study Site Miami Florida 33186 —
Atea Study Site Miami Gardens Florida 33014 —
Atea Study Site North Miami Beach Florida 33162 —
Atea Study Site North Miami Beach Florida 33179 —
Atea Study Site Pembroke Pines Florida 33024 —
Atea Study Site Pompano Beach Florida 33164 —
Atea Study Site Tampa Florida 33607 —
Atea Study Site Tampa Florida 33612 —
Atea Study Site Tampa Florida 33614 —
Atea Study Site Tampa Florida 33615 —
Atea Study Site The Villages Florida 32162 —
Atea Study Site West Miami Florida 33144 —
Atea Study Site West Palm Beach Florida 33409 —
Atea Study Site Eatonton Georgia 31024 —
Atea Study Site Orland Park Illinois 60462 —
Atea Study Site La Vista Nebraska 68128 —
Atea Study Site The Bronx New York 10456 —
Atea Study Site The Bronx New York 10467 —
Atea Study Site Chapel Hill North Carolina 27514 —
Atea Study Site High Point North Carolina 27260 —
Atea Study Site Chickasha Oklahoma 73018 —
Atea Study Site Providence Rhode Island 02903 —
Atea Study Site Greenville South Carolina 29615 —
Atea Study Site Rock Hill South Carolina 29732 —
Atea Study Site Carrollton Texas 75006 —
Atea Study Site Dallas Texas 75230 —
Atea Study Site DeSoto Texas 75115 —
Atea Study Site Forney Texas 75126 —
Atea Study Site Fort Worth Texas 76164 —
Atea Study Site Harlingen Texas 78550 —
Atea Study Site Houston Texas 77065 —
Atea Study Site Kingwood Texas 77339 —
Atea Study Site Lewisville Texas 75057 —
Atea Study Site Mesquite Texas 75150 —
Atea Study Site San Antonio Texas 78215 —
Atea Study Site Splendora Texas 77372 —
Atea Study Site Stafford Texas 77477 —
Atea Study Site Sugar Land Texas 77479 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 202 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05629962, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 13, 2025 · Synced Nov 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05629962 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →